Trial · NCT07901725
Registered outcomes38
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 38
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Occurrence of Treatment-Emergent Adverse Events (TEAEs) | Up to 7 years | Part 1 |
| Primary | Severity of TEAEs | Up to 7 years | Part 1 |
| Primary | Occurrence of Adverse Events of Special Interest (AESI) | Up to 7 years | Part 1 |
| Primary | Severity of AESI | Up to 7 years | Part 1 |
| Primary | Occurrence of Serious Adverse Events (SAEs) | Up to 7 years | Part 1 |
| Primary | Severity of SAEs | Up to 7 years | Part 1 |
| Primary | Achievement of Hematologic Complete Response (HemCR) per International Society of Amyloidosis (ISA) response criteria as determined by Blinded Independent Review Committee (BIRC) | Up to 7 years | Part 2 |
| Secondary | Occurrence and timing of grade 2 or 3 Cytokine Release Syndrome (CRS) | Up to 28 days following first dose of linvoseltamab | Part 1 |
| Secondary | Major Organ Deterioration-Progression-Free Survival (MOD-PFS) as determined by BIRC per modified ISA criteria | Up to 7 years | Part 2 |
| Secondary | Overall Survival (OS) | Up to 7 years | Part 2 |
| Secondary | Occurrence of a graded cardiac response in participants who are cardiac response evaluable at trial entry | Up to 7 years | Part 2 |
| Secondary | Time to cardiac response in participants who are cardiac response evaluable at trial entry | Up to 7 years | Part 2 |
| Secondary | Occurrence of a graded renal response in participants who are renal response evaluable at trial entry | Up to 7 years | Part 2 |
| Secondary | Time to first renal response in participants who are renal response evaluable at trial entry | Up to 7 years | Part 2 |
| Secondary | Achievement of Very Good Partial Response or better (≥VGPR) as assessed by BIRC per ISA response criteria | Up to 7 years | Part 2 |
| Secondary | Achievement of Partial Response or better (≥PR) as assessed by BIRC per ISA response criteria | Up to 7 years | Part 2 |
| Secondary | Duration of Response (DOR) per ISA response criteria | Up to 7 years | Part 2 |
| Secondary | Duration of HemCR per ISA response criteria | Up to 7 years | Part 2 |
| Secondary | Time to Next Treatment (TTNT) | Up to 7 years | Part 2 |
| Secondary | Achievement of HemCR as assessed by the BIRC per ISA response criteria | Up to month 6 | Part 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07901725/registered